Ductal carcinoma is a type of breast cancer that begins in the cells lining the milk ducts. It is the most common form of breast cancer, and it comes in two main forms: one that stays contained inside the duct and one that breaks through and spreads into surrounding breast tissue. Together, these two forms account for the vast majority of breast cancer diagnoses. Understanding the difference between them, and what happens after a diagnosis, is the key to making sense of what this term means in practice.
The Two Main Forms
The distinction between the two types of ductal carcinoma comes down to a single structural boundary: the basement membrane, a thin wall that surrounds each milk duct. When abnormal cells grow inside the duct but have not broken through that wall, the condition is called ductal carcinoma in situ, or DCIS. “In situ” means “in place.” DCIS accounts for about 20% of newly diagnosed breast cancers and is considered noninvasive because the abnormal cells haven’t yet gained the ability to spread.
When those cells do break through the duct wall and begin growing into the fatty tissue of the breast, the diagnosis becomes invasive ductal carcinoma, or IDC. This is the more common form, representing roughly 80% of all breast cancers. IDC has the potential to travel to lymph nodes and other parts of the body, which is why staging and treatment planning become more involved.
There is also an in-between category. DCIS with microinvasion describes cases where tiny clusters of cells have pushed just barely through the duct wall, with no invasive focus larger than 1 millimeter. This accounts for 10% to 20% of DCIS cases and roughly 1% of all breast cancers. It’s treated more like early invasive cancer than pure DCIS.
How Ductal Carcinoma Is Found
DCIS is most often discovered on a routine mammogram before any lump can be felt. The hallmark finding is a pattern of tiny calcium deposits, called microcalcifications, that form inside the ducts. These calcifications take on characteristic shapes: fine linear patterns that trace the path of a duct, fine pleomorphic (irregularly shaped) clusters, or amorphous scattered deposits. When those calcifications appear in a linear or segmental distribution, following the branching path of the duct system, they are associated with malignancy up to 80% of the time.
Invasive ductal carcinoma, by contrast, more often presents as a lump or mass that can sometimes be felt during a physical exam or seen on imaging. Ultrasound and MRI play supporting roles. On MRI, DCIS tends to show up as linear or segmental enhancement patterns, which reflect how the disease tracks along the duct network. Some cases of DCIS produce no calcifications at all, which is one reason MRI is sometimes used as a supplemental screening tool.
Regardless of how it’s found, a tissue biopsy is always needed to confirm the diagnosis. Imaging raises the suspicion, but only examining the cells under a microscope can determine whether the growth is in situ, invasive, or somewhere in between.
Grading: How Aggressive the Cells Look
Once a biopsy confirms ductal carcinoma, a pathologist assigns a grade that reflects how abnormal the cells appear and how quickly they seem to be dividing. The grading system evaluates three features: how much the cells still form normal tube-like duct structures, how irregular the cell nuclei look, and how many cells are actively dividing. Each feature gets a score from 1 (closer to normal) to 3 (more abnormal), and the three scores are added together.
A total score of 3 to 5 corresponds to grade 1 (low grade), meaning the cancer cells still somewhat resemble normal breast tissue and tend to grow slowly. Scores of 6 or 7 indicate grade 2 (intermediate), and 8 or 9 is grade 3 (high grade), where cells look very abnormal and divide rapidly. Grade influences treatment decisions and helps predict how the cancer is likely to behave over time.
Molecular Subtypes of Invasive Ductal Carcinoma
Beyond the grade, invasive ductal carcinoma is classified into subtypes based on which receptors the cancer cells display on their surface. These receptors determine what fuels the cancer’s growth and, critically, which treatments will work against it. The three receptors tested are estrogen receptor (ER), progesterone receptor (PR), and HER2, a growth-promoting protein. About 70% to 75% of invasive breast cancers are estrogen receptor positive.
The four widely recognized subtypes are:
- Luminal A: ER and/or PR positive, HER2 negative, slow growing. This is the most favorable subtype, with a 5-year survival rate of about 94%. These cancers respond well to hormone-blocking therapy and often don’t need aggressive chemotherapy.
- Luminal B: ER positive but faster growing, sometimes PR negative. These tumors are more aggressive than Luminal A, with a 5-year survival rate around 91%. They typically require more intensive treatment.
- HER2 positive: High HER2 expression without hormone receptors. This subtype makes up 10% to 15% of breast cancers and is fast growing, but outcomes have improved significantly with the development of HER2-targeted therapies. Five-year survival is approximately 85%.
- Triple negative: No ER, PR, or HER2. This subtype lacks the three main treatment targets, which limits options to chemotherapy and newer immunotherapy approaches. It tends to be the most aggressive and has the lowest survival rates of the four subtypes.
Staging Invasive Ductal Carcinoma
Staging describes how far the cancer has spread and is one of the strongest predictors of outcome. The system used is called TNM: T for tumor size, N for lymph node involvement, and M for whether the cancer has reached distant organs.
Tumor size categories are straightforward. T1 means the tumor is 20 millimeters (about ¾ inch) or smaller. T2 is larger than 20 millimeters but no bigger than 50 millimeters. T3 is anything over 50 millimeters. Lymph node status is assessed by checking whether cancer cells have reached the nodes under the arm. N0 means the nodes are clear, while increasing N numbers reflect greater lymph node involvement.
The overall stage, built from these components, directly correlates with survival. For localized breast cancer (confined to the breast with no spread), the 5-year relative survival rate is greater than 99%, based on data from women diagnosed between 2015 and 2021. When cancer has spread to nearby lymph nodes (regional), that drops to 87%. For distant spread to other organs, the 5-year survival rate is 33%.
Treatment for DCIS
Because DCIS has not spread beyond the duct, the goal of treatment is to remove it completely and reduce the chance it develops into invasive cancer. The standard approach is breast-conserving surgery (lumpectomy), often followed by radiation. Data from the Ontario Cancer Registry showed that adding radiation after lumpectomy reduced the 10-year recurrence rate from about 20% to 13%. Without radiation, roughly 1 in 5 women experienced a local recurrence within a decade.
For larger areas of DCIS or cases where clear margins can’t be achieved, mastectomy may be recommended. Lymph node sampling is not routine for DCIS, since by definition the cancer hasn’t invaded tissue that connects to the lymph system. However, guidelines support checking the sentinel lymph node when DCIS is extensive (larger than 50 millimeters), when mastectomy is planned, or when the pathology suggests a higher risk of finding hidden invasive disease. Factors that raise that risk include high-grade DCIS, the presence of tissue death (necrosis) within the tumor, and a palpable mass.
Treatment for Invasive Ductal Carcinoma
Invasive ductal carcinoma requires a broader treatment approach because of its potential to spread. Surgery, either lumpectomy with radiation or mastectomy, remains the foundation. For invasive cancer, sentinel lymph node biopsy is standard practice to determine whether cancer cells have reached the nodes, which directly affects staging and further treatment decisions.
After surgery, treatment is tailored to the cancer’s molecular subtype. For hormone receptor positive cancers (the Luminal A and B subtypes), hormone-blocking therapy is a cornerstone. Nearly all women with ER-positive breast cancer are candidates for at least five years of this treatment. For premenopausal women with low-risk tumors, a five-year course of tamoxifen, which blocks estrogen from fueling cancer cells, is the preferred approach. Postmenopausal women typically start with aromatase inhibitors, which work by shutting down estrogen production in fat and adrenal tissue.
For women with higher-risk features, such as positive lymph nodes, larger tumors, or high-grade disease, hormone therapy may be extended to 10 years. Treatment plans may also combine medications, pairing ovarian suppression with tamoxifen or an aromatase inhibitor for premenopausal women facing more aggressive cancers. HER2-positive cancers receive targeted therapies designed to block the HER2 protein, and chemotherapy is used across subtypes when the cancer’s characteristics or stage warrant it.
DCIS as a Precursor to Invasive Cancer
DCIS is considered the direct precursor to invasive ductal carcinoma. Left untreated, some proportion of DCIS will progress to invasive cancer over time. This is the rationale for treating it, even though it is technically noninvasive. However, not all DCIS progresses, and one of the ongoing challenges in breast cancer care is distinguishing the cases that truly need aggressive treatment from those that might be safely monitored. Low-grade DCIS, in particular, grows slowly and may pose minimal risk over a woman’s lifetime, while high-grade DCIS with necrosis behaves more urgently and carries a greater chance of harboring or developing into invasive disease.